Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining

Molecular Cancer Research

Volumn 3, Issue 5, 2005, Pages 277-285

  Boeckman, Heather J ^a   Trego, Kelly S ^a   Turchi, John J ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA DEPENDENT PROTEIN KINASE;

ANIMAL CELL; ARTICLE; CANCER; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SENSITIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIZATION; SENSITIZATION;

ANIMALS; BASE SEQUENCE; CATALYSIS; CELL LINE; CELL SURVIVAL; CISPLATIN; DNA; DNA DAMAGE; DNA REPAIR; GENETIC VECTORS; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; RECOMBINATION, GENETIC;

EID: 18544373369     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-04-0032     Document Type: Article

References (67)

1. Lieber MR, Ma YM, Pannicke U, Schwarz K. Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 2003;4:712-20.
2. Keys HM. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1144-53.
3. Rose PG. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;341:708.
4. Myint WK, Ng C, Raaphorst GP. Examining the non-homologous repair process following cisplatin and radiation treatments. Int J Radiat Biol 2002;78:417-24.
5. Dolling JA, Boreham DR, Brown DL, Mitchel REJ, Raaphorst GP. Modulation of radiation-induced strand break repair by cisplatin in mammalian cells. Int J Radiat Biol 1998;74:61-9.
6. Ormerod MG, O'Neill CF, Robertson D, Harrap KR. Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant intemucleosomal degradation of DNA. Exp Cell Res 1994;211:231-7.
7. Henkels KM, Turchi JJ. Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines. Cancer Res 1997;57:4488-92.
8. Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 1999;59:3077-83.
9. Calsou P, Salles B. Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin. Cancer Chemother Pharmacol 1993;32:85-9.
10. Koberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR. DNA repair capacity and cisplatin sensitivity of human testis rumour cells. Int J Cancer 1997;70:551-5.
11. Lai GM, Ozols RF, Smyth JF, Young RC, Hamilton TC. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 1988;37:4597-600.
12. Pouget JP, Douki T, Richard MJ, Cadet J. DNA damage induced in cells by γ and UVA radiation as measured by HPLC/GC-MS and HPLC-EC and comet assay. Chem Res Toxicol 2000;13:541-9.
13. Utsumi H, Tano K, Takata M, Takeda S, Elkind MM. Requirement for repair of DNA double-strand breaks by homologous recombination in split-dose recovery. Radiat Res 2001;155:680-6.
14. Richardson C, Jasin M. Coupled homologous and nonhomologous repair of a double-strand break preserves genomic integrity in mammalian cells. Mol Cell Biol 2000;20:9068-75.
15. Liang F, Han MG, Romanienko PJ, Jasin M. Homology-directed repair is a major double-strand break repair pathway in mammalian cells. Proc Natl Acad Sci USA 1998;95:5172-7.
16. Sargent RG, Brenneman MA, Wilson JH. Repair of site-specific double-strand breaks in a mammalian chromosome by homologous and illegitimate recombination. Mol Cell Biol 1997;17:267-77.
17. West R, Yaneva M, Lieber M. Productive and nonproductive complexes of Ku and DNA-dependent protein kinase at DNA termini. Mol Cell Biol 1998;18:5908-20.
18. Lees-Miller SP. The DNA-dependent protein kinase, DNA-PK: 10 years and no ends in sight. Biochem Cell Biol 1996;74:503-12.
19. Walker JR, Corpina RA, Goldberg J. Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. Nature 2001;412:607-14.
20. DeFazio LG, Stansel RM, Griffith JD, Chu G. Synapsis of DNA ends by DNA-dependent protein kinase. EMBO J 2002;21:3192-200.
21. Gottlieb TM, Jackson SP. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell 1993;72:131-42.
22. cs induces inward translocation of Ku protein. Nucleic Acids Res 1999;27:4679-86.
23. Turchi JJ, Henkels KM, Zhou Y. Cisplatin-DNA adducts inhibit translocation of the Ku subunits of DNA-PK. Nucleic Acids Res 2000;28:4634-41.
24. Ma YM, Pannicke U, Schwarz K, Lieber MR. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 2002;108:781-94.
25. Turchi JJ, Huang L, Murante RS, Kim Y, Bambara RA. Enzymatic completion of mammalian lagging-strand DNA replication. Proc Natl Acad Sci U S A 1994;91:9803-7.
26. Murante RS, Huang L, Turchi JJ, Bambara RA. The calf 5′- to 3′-exonuclease is also an endonuclease with both activities dependent on primers annealed upstream of the point of cleavage. J Biol Chem 1994;269:1191-6.
27. Carney JP, Maser RS, Olivares H, et al. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 1998;93:477-86.
28. Chamankhah M, Xiao W. Formation of the yeast Mre11-Rad50-Xrs2 complex is correlated with DNA repair and telomere maintenance. Nucleic Acids Res 1999;27:2072-9.
29. de Jager M, Dronkert MLG, Modesti M, Beerens CEMT, Kanaar R, van Gent DC. DNA-binding and strand-annealing activities of human Mre11: implications for its roles in DNA double-strand break repair pathways. Nucleic Acids Res 2001;29:1317-25.
30. Trujillo KM, Yuan SSF, Lee EYHP, Sung P. Nuclease activities in a complex of human recombination and DNA repair factors Rad50, Mre11, p95. J Biol Chem 1998;273:21447-50.
31. Baumann P, West SC. DNA end-joining catalyzed by human cell-free extracts. Proc Natl Acad Sci U S A 1998;95:14066-70.
32. Critchlow SE, Bowater RP, Jackson SP. Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV. Curr Biol 1997;7:588-98.
33. McElhinny SAN, Snowden CM, McCarville J, Ramsden DA. Ku recruits the XRCC4-ligase IV complex to DNA ends. Mol Cell Biol 2000;20:2996-3003.
34. Yu YP, Wang W, Ding Q, et al. DNA-PK phosphorylation sites in XRCC4 are not required for survival after radiation or for V(D)J recombination. DNA Repair 2003;2:1239-52.
35. Allalunis-Turner MJ, Barron GM, Day RS, Dobler KD, Mirzayans R. Isolation of 2 cell-lines from a human-malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs. Radiat Res 1993;134:349-54.
36. Chou TC, Talalay P. Quantitative-analysis of dose-effect relationships-the combined effects of multiple-drugs or enzyme-inhibitors. Adv Enzyme Regul 1984;22:27-55.
37. Azzariti A, Xu HM, Porcelli L, Paradiso A. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with gefitinib (Iressa,(TM), ZD1839). Biochem Pharmacol 2004;68:135-44.
38. George P, Bali P, Cohen P, et al. Cotreatment with 17-allylamino- demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 2004;64:3645-52.
39. Maggio SC, Rosato RR, Kramer LB, et al. The histone deacetylase inhibitor MS-275 interacts synergisticalty with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 2004;64:2590-600.
40. Gorodetsky R, Levy-Agababa F, Mou X, Vexier A. Combination of cisplatin and radiation in cell culture: effect of duration of exposure to drug and timing of irradiation. Int J Cancer 1998;75:635-42.
41. Raaphorst GP, Wang G, Stewart D, Ng CE. Concomitant low dose-rate irradiation and cisplatin treatment in ovarian carcinoma cell lines sensitive and resistant to cisplatin treatment. Int J Radiat Biol 1996;69:623-31.
42. Wilkins DE, Ng CE, Raaphorst GP. Cell cycle perturbations in cisplatin-sensitive and resistant human ovarian carcinoma cells following treatment with cisplatin and low dose rate irradiation. Cancer Chemother Pharmacol 1997;40:159-66.
43. Chan DW, Gately DP, Urban S, et al. Lack of correlation between ATM protein expression and tumour cell radiosensitivity. Int J Radiat Biol 1998;74:217-24.
44. Iliakis G, Wang Y, Guan J, Wang HC. DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 2003;22:5834-47.
45. Canman CE, Lim DS, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998;281:1677-9.
46. Dolling JA, Boreham DR, Brown DL, Raaphorst GP, Mitchel REJ. Cisplatin-modification of DNA repair and ionizing radiation lethality in yeast, Saccharomyces cerevisiae. Mutat Res 1999;433:127-36.
47. Yamaguchi-Iwai Y, Sonoda E, Buerstedde JM, et al. Homologous recombination, but not DNA repair, is reduced in vertebrate cells deficient in RAD52. Mol Cell Biol 1998;18:6430-5.
48. Bezzubova O, Silbergleit A, Yamaguchilwai Y, Takeda S, Buerstedde JM. Reduced X-ray resistance and homologous recombination frequencies in a RAD54(-/-) mutant of the chicken DT40 cell line. Cell 1997;89:185-93.
49. Takata M, Sasaki MS, Sonoda E, et al. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 1998;17:5497-508.
50. Yoo S, Kimzey A, Dynan WS. Photocross-linking of an oriented DNA repair complex-Ku bound at a single DNA end. J Biol Chem 1999;274:20034-9.
51. Pawelczak CS, Andrews BJ, Turchi JJ. Differential activation of DNA-PK based on DNA strand orientation and sequence bias. Nucleic Acids Res 2005;33:152-61.
52. Hashimoto M, Rao S, Tokuno O, et al. DNA-PK: the major target for wortmannin-mediated radiosensitization by the inhibition of DSB repair via NHEJ pathway. J Radiat Res (Tokyo) 2003;44:151-9.
53. Solomon B, Ball DL, Richardson G, et al. Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer. Lung Cancer 2003;41:353-61.
54. Martenson JA, Vigliotti APG, Pilot HC, et al. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003;55:1305-10.
55. Sood BM, Timmins PF, Gorla GR, et al. Concomitant cisplatin and extended field radiation therapy in patients with cervical and endometrial cancer. Int J Gynecol Cancer 2002;12:459-64.
56. Rosenthal DI, Yom S, Liu L, et al. A Phase I study of SPI-077 (Stealth((R)) liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest New Drugs 2002;20:343-9.
57. Groen HJ, Sleijfer S, Meijer C, et al. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. Br J Cancer 1995;72:1406-11.
58. Yang J, Yu YN, Hamrick HE, Duerksen-Hughes PJ. ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinogenesis 2003;24:1571-80.
59. Durocher D, Jackson SP. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 2001;13:225-31.
60. Yazlovitskaya EM, Persons DL. Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin. Anticancer Res 2003;23:2275-9.
61. Mascharak PK, Sugiura Y, Kuwahara J, Suzuki T, Lippard S. Alteration and activation of sequence-specific cleavage of DNA by bleomycin in the presence of the antitumor drug cis-diamminedichloroplatinum(II). Proc Natl Acad Sci U S A 1983;80:6795-8.
62. Huang LC, Clarkin KC, Wahl GM. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G(I) arrest. Proc Natl Acad Sci U S A 1996;93:4827-32.
63. Allen C, Halbrook J, Nickoloff JA. Interactive competition between homologous recombination and non-homologous end joining. Mol Cancer Res 2003;1:913-20.
64. Turchi JJ, Patrick SM, Henkels KM. Mechanism of DNA-dependent protein kinase inhibition by cis-diamminedichloroplatinum(II)-damaged DNA. Biochemistry 1997;36:7586-93.
65. Turchi JJ, Henkels KM. Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase. J Biol Chem 1996;271:13861-7.
66. Patrick SM, Turchi JJ. Replication protein A (RPA) binding to duplex cisplatin-damaged DNA is mediated through the generation of single-stranded DNA. J Biol Chem 1999;274:14972-8.
67. Wood RD, Robins P, Lindahl T. Complementation of the xeroderma pigmentosum DNA repair defect in cell-free extracts. Cell 1988;53:97-106.